Synlogic reports Q3 net loss $16M; PKU Phase 2 shows proof of concept, moving to Phase 3

SYNLOGIC, INC.

2022-Q3 EPS reported -$0.91 revenue$1,162,000

Interim Phase 2 SynPheny-1 data: SYNB1618 achieved proof of concept with statistically significant Phe reduction in PKU patients.
SYNB1934 showed 2x improvement in Phe metabolism biomarkers vs SYNB1618; Phase 3 start planned in 2022.
Cash, equivalents and short-term investments $150.1M as of Sept 30, 2021; net proceeds $48.4M from public offering.
Revenue $0.9M from Roche IBD collaboration; first milestone payment earned; no further SYNB1891 studies planned.
Net loss $16.0M ($0.29/share) vs $13.2M ($0.36/share) in Q3 2020; R&D expense $13.4M, G&A $3.6M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.